Leerdoelen lipo en injectie 2020

* Geschiedenis insuline pennaald
* Evidence - FITTER – V&VN richtlijnen –Diabetes in NL
* Huiddikte, welke naaldlengte en welke injectietechniek
* Technologie pennaald
* Lipohypertrofie ten gevolge van onjuiste injectie techniek
* Oorzaken lipohypertrofie
* Gevolgen Lipohypertrofie
* Voorkomen en minimaliseren
* Mogelijke problemen bij injectie

Referenties

1. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of Lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct;39(5):445-53. doi:10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22.
2. Ji L, Li Q, Wei G. Lipohypertrophy - prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. Submitted, J. Diabetes. ITQ
3. Vardar B, Kizilci S. Incidence of Lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract 2007;77:231-6.
4. Saez-de Ibarra L, Gallego F. Factors related to Lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. Pract Diab Int 1998;15:9-11.
5. Frid et al. Worldwide Injection Technique Questionnaire Study: Population Parameters and Injection Practices. Mayo Clin Proc. September 2016;91(9):1212-1223
6. Giorgio Grassi, MD, Paola Scuntero, RN , Rosalba Trepiccioni, RN, Francesca Marubbi, PhD, Kenneth Strauss, MD. Optimizing insulin injection technique and its effect on blood glucose control. Journal of Clinical & Translational Endocrinology. 2014. 1: p145-150
7. Smith M., Clapham L. & Strauss K. UK Lipohypertrophy interventional study. Diabetes Research and Clinical Practice. 126 (2017) 248-253
8. Insulin-induced Lipohypertrophy: Report of a Case with Histopathology Junji FUJIKURA, Muneya FUJIMOTO, Shintaro YASUE, Michio NOGUCHISusanne Famulla, Ulrike Hövelmann, Annelie Fischer, Hans-Veit Coester, Lutz Heinemann, Lars Kaltheuner, Laurence Hirsch, Tim Heise. Lipohypertrophy (LHT) Leads to Blunted, More Variable Insulin Absorption and Action in Patients with Type 1 Diabetes (T1DM). Abstract 2015 ADA.
9. Ulrike Hovelmann, Susanne Famulla, Lidia Hermanski, Annelie Fischer, Lutz Heinemannn, Matthias Kaltheuner, Laurence Hirsch, Tim Heise,. Insulin Injection into Regions with Lipohypertrophy (LHT) Worsens
10. Qifu Li, Linong Ji, Zilin Sun, Guijun Qin, Zheng Wei, Junhao Liu, Luan Luan, Laurence Hirsch. Lipohypertrophy (LH) Prevalence Varies Widely Between Chinese Cities - Need For Consistent LH Diagnostic Methods. Abstract submitted to 2015 ADA.
11. Famulla S, et. al. Lipohypertrophy Leads to Blunted, More Variable Insulin Absorption and Action in Patients with Type 1 Diabetes. Diabetes. 2015; 64 (suppl1). Poster presented at ADA meeting, Boston, MA. June 2015.
12. Hövelmann U, et. al. Insulin Injection into Regions with Lipohypertrophy (LH) Worsens Postprandial (PP) Blood Glucose (BG) Versus Injections into Normal Adipose Tissue (NAT). 2015; 64 (suppl1). Poster presented at ADA meeting, Boston, MA. June 2015.
13. Clapham L (2015) Injection technique education and follow-up: The key to ensuring optimal glycaemic control. *Journal of Diabetes Nursing* 19: 152–5
14. Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs--same or different? Value Health. 2009; 12(4): 402-4. doi: 10.1111/j.1524-4733.2008.00476\_1.x.
15. Stratton IM, et al. British Medical Journal. 2000; 321: 405-412
16. Porter M.  What is value in health care?  N Engl J Med. 2010; 363(26):2477-2481.